Report
by
Public Health Ontario
Release Date
2017
Geography
Canada
Language of Resource
English
Full Text Available
Yes
Open Access / OK to Reproduce
No
Peer Reviewed
No
Objective
This Evidence Brief asks: What is the evidence of effectiveness of supervised injectable opioid agonist treatment with diacetylmorphine (DAM) or hydromorphone (HDM) on treatment retention (i.e., individual remaining on treatment), drug use, social, health or other outcomes among people with opioid use disorder compared to patients using another treatment or no treatment?
Findings/Key points
- siOAT has been studied primarily among patients who have undergone methadone treatment in the past.
- siOAT trials have demonstrated significant benefits for retention in treatment, reducing the use of street drugs, and reducing illegal activities in this population.
- siOAT is associated with a greater number of serious adverse events compared with methadone, but these can be managed in a supervised setting.
- Hydromorphone is as effective as diacetylmorphine for siOAT, with fewer adverse events.
Keywords
Evidence base
Safer supply
